Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 8/20 | 0.49 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31676999 | 1.00 | KDM5B (0.49) | KDM5BEGLN2TSHRPGRMEN1 | |
| SCHEMBL20074110 | 0.86 | KDM5B (0.48) | KDM5BEGLN2TSHRPGRCYP1A2 | |
| SCHEMBL20074112 | 0.86 | TSHR (0.39) | KDM5BTSHR | |
| SCHEMBL20074303 | 0.85 | CCNB2 (0.47) | KDM5BEGLN2TSHRMEN1HPGD | |
| SCHEMBL20074230 | 0.85 | KDM5B (0.57) | KDM5BTSHRMEN1HPGDKMT2A | |
| SCHEMBL20074277 | 0.85 | KDM5B (0.42) | KDM5BEGLN2TSHRMEN1HPGD | |
| SCHEMBL21681717 | 0.84 | KDM5B (0.50) | KDM5BEGLN2TSHR | |
| SCHEMBL21721688 | 0.84 | KDM5B (0.52) | KDM5BTSHRCHEK1 | |
| SCHEMBL21681725 | 0.83 | KDM5B (0.51) | KDM5BEGLN2TSHRPGR | |
| SCHEMBL20074315 | 0.83 | KDM5B (0.51) | KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975084-B2 | KDM5 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200048258-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048258-A1 | KDM5 INHIBITORS | KDM5A, KDM5B, KDM5C | KDM5B 2/4885EGLN2 600/4885TSHR 4342/4885 |
| US-10975084-B2 | KDM5 inhibitors | KDM5A, KDM5B, KDM5C | KDM5B 2/4885EGLN2 600/4885TSHR 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.